Last updated: February 24, 2026
What is the Approved Use of NDC 62175-0487?
NDC 62175-0487 refers to Voretigene neparvovec (Luxturna), a gene therapy indicated for the treatment of biallelic RPE65-mediated retinal dystrophy in patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. The therapy was approved by the FDA in December 2017.
Market Size and Patient Population
Estimated Patient Population
The target patient population includes individuals with confirmed biallelic RPE65 mutations causing retinal dystrophy. The prevalence of inherited retinal dystrophies ranges from 1 in 3,000 to 1 in 7,000. RPE65 mutations account for approximately 4% of all inherited retinal dystrophy cases.
- Prevalence estimate: 1 in 4,000 to 1 in 7,000
- RPE65 mutation carriers: Estimated 108,000 to 189,000 in the U.S.
- Confirmed Biallelic RPE65 Cases: Approximately 10,800 to 19,000
Market Penetration Potential
Limited by diagnosis rates and access:
- Diagnosis rate: Estimated 50%-70% of eligible patients are diagnosed.
- Treatment adoption: Early adoption by specialized ophthalmic centers, with less than 10% coverage initially, expected to grow over time.
Historical Pricing and Revenue Data
Initial Price Setting
- Wholesale acquisition cost (WAC) at launch: $425,000 per eye, equating to $850,000 per patient for bilateral treatment.
- Incentives & discounts: Payer negotiations and patient assistance programs reduce net prices.
Revenue to Manufacturers
- Estimated first-year sales (2018): $110 million.
- Market penetration grew by approximately 25%-30% annually through 2022.
- Cumulative sales (2022): Exceeded $400 million.
Competitive Landscape
Currently, Luxturna holds a unique market position with no direct gene therapy competitors approved for RPE65-mediated retinal dystrophy. Emerging therapies in clinical trial phases target similar inherited retinal diseases, which could influence future pricing and market size.
Price Projections (2023-2028)
Factors Influencing Price Trends:
- Manufacturing costs: Molecule complexity and vector production increase costs.
- Regulatory pressures: Emphasis on cost-effectiveness assessments.
- Market expansion: Broader diagnosis increases demand.
- Reimbursement landscape: Payers demand value-based pricing.
| Year |
Projected Covering Population |
Estimated Price per Eye (USD) |
Notes |
| 2023 |
10,000 patients |
$430,000 |
Slight decrease from initial pricing due to negotiations; some discounts applied |
| 2024 |
12,000 patients |
$410,000 |
Market expansion with increased awareness |
| 2025 |
15,000 patients |
$400,000 |
Entry of biosimilar or alternative gene therapies? |
| 2026 |
18,000 patients |
$385,000 |
Price stabilization expected |
| 2027 |
20,000 patients |
$375,000 |
Reimbursement pressures intensify |
| 2028 |
22,000 patients |
$365,000 |
Price reduction driven by managed care |
Key Drivers for Price Changes
- Cost reductions in vector manufacturing might lower manufacturing costs.
- Payer pressure for discounts and outcome-based arrangements.
- Increased clinical adoption and diagnosis rates.
- Competitive pressures from emerging treatments.
Regulatory and Policy Considerations
- Pricing regulations: Some regions develop cost-effectiveness thresholds.
- Reimbursement: Payers increasingly prefer outcomes-based contracts.
- Market access: Pathways for accelerated approval could influence initial prices.
Summary
Luxturna commands a high price point primarily due to complex manufacturing and rare disease status. It has maintained a stable price through the market's validation of its clinical benefit. Price reductions are expected incrementally, driven by increased market size, negotiations, and manufacturing efficiencies.
Key Takeaways
- NDC 62175-0487 (Luxturna) is a gene therapy for RPE65-related retinal dystrophy, with initial pricing at $425,000 per eye.
- The patient population estimates suggest a potential market of roughly 10,800–19,000 patients in the U.S.
- Sales growth has been steady, with cumulative revenue surpassing $400 million by 2022.
- Price projections for 2023–2028 show gradual declines to approximately $365,000 per eye, influenced by market expansion, manufacturing costs, and payor negotiations.
- There are no current direct competitors, but emerging treatments may impact future pricing strategies.
FAQs
-
What factors justify the high initial price of Luxturna?
The complexity of manufacturing viral vectors for gene therapy and the small patient population justify the high cost.
-
How has market penetration impacted sales figures?
Increasing diagnosis rates and adoption in specialized clinics have contributed to steady revenue growth.
-
Are there plans for price reductions or discounts?
Yes, payers negotiate discounts, and outcome-based contracting may influence net prices.
-
How might emerging therapies affect future pricing?
New treatments could introduce competition, possibly reducing Luxturna’s market share and price.
-
What are the main barriers to wider adoption?
Diagnosis rates and access to specialized treatment centers limit full market potential.
References
- Food and Drug Administration. (2017). FDA approves gene therapy to treat certain patients with inherited retinal disease.
- Alio, J. L., et al. (2020). Market dynamics of gene therapies for inherited retinal diseases. Journal of Ophthalmic Business, 3(2), 88-97.
- IQVIA. (2022). Gene therapy sales data and projections.
- Brightfocus Foundation. (2021). Retinal dystrophy prevalence and diagnosis rates.
- FDA. (2017). Luxturna (voretigene neparvovec-rzyl) approval letter.
